Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.66 |
| ▸ | CA2 | P00918 | 11/20 | 0.62 |
| ▸ | CA1 | P00915 | 9/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | SHBG | P04278 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069118 | 1.00 | TAAR1 (0.66) | TAAR1CA2CA1ALDH1A1KMT2A | |
| SCHEMBL7396578 | 0.83 | TAAR1 (0.87) | TAAR1CA2CA1ALDH1A1KMT2A | |
| SCHEMBL4257064 | 0.78 | CA2 (0.53) | TAAR1CA2CA1ALDH1A1KMT2A | |
| SCHEMBL4257061 | 0.78 | CA2 (0.53) | TAAR1CA2CA1ALDH1A1KMT2A | |
| SCHEMBL28155671 | 0.78 | TAAR1 (0.82) | TAAR1CA2CA1ALDH1A1KMT2A | |
| SCHEMBL21543817 | 0.75 | TAAR1 (0.64) | TAAR1CA2CA1ALDH1A1KMT2A | |
| SCHEMBL21543818 | 0.75 | TAAR1 (0.64) | TAAR1CA2CA1ALDH1A1KMT2A | |
| SCHEMBL5070825 | 0.75 | TAAR1 (0.64) | TAAR1CA2CA1ALDH1A1KMT2A | |
| SCHEMBL5070824 | 0.75 | TAAR1 (0.64) | TAAR1CA2CA1ALDH1A1KMT2A | |
| SCHEMBL31140006 | 0.75 | TAAR1 (0.64) | TAAR1CA2CA1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432228-B2 | Inhibitor against biosynthesis of abscisic acid | RIKEN (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7098365-B2 | Abscisic acid biosynthesis inhibitor | RIKEN (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20060148650-A1 | Inhibitor against biosynthesis of abscisic acid | RIKEN (JP) | 2006-07-06 | — | — | US | disclosed |
| US-20050014651-A1 | Abscisic acid biosynthesis inhibitor | RIKEN (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1439165-A1 | ABSCISIC ACID BIOSYNTHESIS INHIBITOR | Riken (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148650-A1 | Inhibitor against biosynthesis of abscisic acid | COASY, BLVRB, ME1 | TAAR1 2570/4885CA2 1557/4885CA1 3294/4885 |
| US-20050014651-A1 | Abscisic acid biosynthesis inhibitor | COASY, BLVRB, ME1 | TAAR1 2252/4885CA2 1210/4885CA1 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.